Insulin - BTG/Kings College London
Latest Information Update: 21 Jan 2022
At a glance
- Originator Kings College London
- Developer BTG
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 26 Jun 2012 No development reported - Phase-I for Type-1 diabetes mellitus in United Kingdom (unspecified route)
- 26 Jun 2012 No development reported - Phase-I for Type-2 diabetes mellitus in United Kingdom (unspecified route)